NCT02105675

Phase II Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer

Randomized, Open-label, Parallel-group, Multi-centre Phase II Clinical Trial of Active Cellular Immunotherapy With Preparation DCVAC/PCa in Patients With Castrate-resistant Prostate Cancer

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: SOTIO a.s. · Industry
• Sex: Male
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether DCVAC/PCa added onto Standard of Care therapy can improve survival times for patients with Metastatic Castration Resistant Prostate Cancer

Conditions

• Prostate Cancer
• Prostate Cancer Metastatic

Interventions

Type	Name	Description
BIOLOGICAL	Dendritic Cells DCVAC/PCa	DCVAC/PCa is the experimental therapy added on to Docetaxel
DRUG	Docetaxel	Docetaxel is Standard of Care First Line Chemotherapy

Timeline

• Start date: 2012-02-01
• Primary completion: 2014-03-01
• Completion: 2017-02-20
• First posted: 2014-04-07
• Last updated: 2017-05-24

Locations

10 sites across 1 country: Czechia